Randomized trial · people
Abaloparatide raised hip BMD around a virtual hip stem in ACTIVE
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In postmenopausal women with osteoporosis, abaloparatide raised bone density in thigh-bone regions around a simulated hip stem, though whether that improves hip replacement outcomes was not tested.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 500
- Published
- 2024
- Journal
- J Bone Joint Surg Am
What they tested
The team wanted to know whether abaloparatide improves bone density in the upper thigh-bone regions that would surround the stem of a hip replacement.
How the study was done
A post hoc analysis (a look back at data collected for another purpose) of the randomized, placebo-controlled phase 3 ACTIVE trial, using hip DXA scans (a type of x-ray bone scan) from 500 randomly picked postmenopausal women with osteoporosis: 250 on abaloparatide and 250 on placebo, scanned at 0, 6 and 18 months. The scans were turned into 3D models, a tapered hip stem was placed virtually, and bone was measured in the Gruen zones (standard regions around a hip stem) 1, 2, 6 and 7.

What they found
Compared with placebo, women on abaloparatide had larger gains in integral volumetric BMD (overall bone density through the whole bone volume) in every zone at both 6 and 18 months. By 18 months, cortical thickness, cortical volumetric BMD and cortical surface BMD (measures of the dense outer bone layer) had also risen more in every zone, and cortical surface BMD was already higher in zones 1, 6 and 7 at 6 months. Trabecular volumetric BMD (density of the spongy inner bone) rose more in zones 1 and 7 at both time points.
What it doesn’t show
This was a post hoc analysis, and the hip stem was only placed virtually on scans, so it measured bone density rather than any real implant. It did not test surgical outcomes such as fractures around an implant or implant stability, and it included only postmenopausal women with osteoporosis.
The paper
Sheth et al. Effects of Abaloparatide on Bone Mineral Density in Proximal Femoral Regions Corresponding to Arthroplasty Gruen Zones: A Study of Postmenopausal Women with Osteoporosis. J Bone Joint Surg Am. 2024.
The compound
More studies on Abaloparatide
- Abaloparatide, teriparatide beat other drugs on spine BMD in menMeta-analysis · people · 2025
- Abaloparatide: larger hip BMD gains than teriparatide at 24 weeksMeta-analysis · people · 2023
- Abaloparatide improved hip geometry vs placebo in ACTIVE-JRandomized trial · people · 2023
- Abaloparatide then alendronate: 84% lower vertebral fracture riskRandomized trial · people · 2018
- Abaloparatide: normal bone biopsies after up to 18 months in ACTIVERandomized trial · people · 2017
- Abaloparatide: fewer new vertebral fractures vs placebo in ACTIVERandomized trial · people · 2016
- Every study on Abaloparatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.